Patents by Inventor Rinat Neuroscience Corp.

Rinat Neuroscience Corp. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130164308
    Abstract: The present invention provides antagonizing antibodies that bind to S. aureus alpha-toxin. The invention further provides a method of obtaining such antibodies and antibody encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies for the treatment and/or prevention of staphylococcal disease, including, for example, pneumonia, bacteremia, sepsis, eye infection, and abscess.
    Type: Application
    Filed: December 18, 2012
    Publication date: June 27, 2013
    Inventor: RINAT NEUROSCIENCE CORP.
  • Publication number: 20130122020
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 16, 2013
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventor: Rinat Neuroscience Corp.
  • Publication number: 20130071921
    Abstract: The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1+ cells. Also provided are nucleic acids encoding anti-Dkk-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-Dkk-1 antibodies and fragments thereof. Also provided are methods of preparing the antibodies and fragments thereof of the invention. Also provided are bone anabolic agents. Pharmaceutical compositions comprising the antibodies or fragments thereof of the invention are also provided.
    Type: Application
    Filed: November 19, 2012
    Publication date: March 21, 2013
    Applicants: RINAT NEUROSCIENCE CORP., PFIZER INC.
    Inventors: PFIZER INC., RINAT NEUROSCIENCE CORP.
  • Publication number: 20130028916
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Application
    Filed: September 26, 2012
    Publication date: January 31, 2013
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventor: Rinat Neuroscience Corp.